静脉溶栓治疗≥80岁急性缺血性脑卒中患者的疗效和安全性的进展  

Progress of efficacy and safety of intravenous thrombolysis in the treatment of patients with acute ischemic stroke over 80 years of age

作　　者：林冠 王翔宇[1] 周丽 孙世玉 刘园捷 Lin Guan;Wang Xiangyu;Zhou Ll;Sun ShiYu;Liu YuanJie(Three Gorges University Third Clinical Medical College Gezhouba Group Central Hospital Neurology Department Hubei Yichang 443002)

机构地区：[1]三峡大学第三临床医学院葛洲坝集团中心医院神经内科,湖北宜昌443002

出　　处：《中国社区医师》2019年第3期11-12,共2页Chinese Community Doctors

摘　　要：研究表明,年龄是影响卒中发病风险及转归的重要危险因素之一,年龄≥80岁的患者急性缺血性卒中的发病率明显增高。目前我国急性缺血性脑卒中患者静脉溶栓治疗率仍非常低,仅有2.4%,其中使用rt-PA(阿替普酶)溶栓治疗仅1.6%。高龄患者溶栓率更低。本文主要探讨≥80岁的急性缺血性脑卒患者静脉应用rt-PA溶栓的疗效和安全性。Research shows that age is one of the most important risk factors for stroke risk and prognosis,the incidence of acute ischemic stroke is significantly higher in patients aged 80 and above.At present,the rate of intravenous thrombolysis for acute ischemic stroke in China is still very low,the ratio is 2.4%,among them,the ratio of thrombolytic therapy using rt-PA(alteplase)is 1.6%.The thrombolytic rate of elderly patients is lower.This article mainly discusses the efficacy and safety of intravenous thrombolysis with rt-PA in the treatment of patients with acute ischemic stroke over 80 years of age.

关 键 词：阿替普酶 急性缺血性脑卒中 静脉溶栓 ≥80岁患者 

分 类 号：R743.3[医药卫生—神经病学与精神病学]